The agreement settles allegations made by 49 states that the consulting firm advised Purdue Pharma and other opioid drugmakers to ramp up sales during a time when the government and pharmaceutical industry was aware that hundreds of thousands of Americans had died from opioid overdoses.
McKinsey was ordered to pay $478 million of the settlement within 60 days, and the money will be allocated for opioid treatment, prevention and recovery programs. MIO Partners, a hedge fund wholly owned by McKinsey, holds indirect stakes in addiction treatment centers and a drugmaker that manufactures products that treat opioid overdoses.
Investment records also show MIO Partners held stakes in companies that profited from increased opioid usage during the time McKinsey was advising opioid drugmakers to “turbocharge” their opioid sales, according to NBC News.
A McKinsey spokesperson told NBC News the firm “has no visibility into or control of how settlement money will be used by the states.” He also said McKinsey and MIO Partners are “operationally separate.”
More articles on opioids:
Former Insys Therapeutics CEO to pay $5M for alleged improper opioid marketing
Ohio physician gets 2-year prison sentence for illegal opioid distribution
McKinsey reaches $573M settlement with 47 states for role in opioid epidemic
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
